Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci161 in Healthy Adult Participants
NCT07476586Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- May 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GenSci161 (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events. Started Apr 2026; status: recruiting.
02
Drugs
GenSci161
Beyond the preview
Go deeper on NCT07476586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476586.